Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Hanna K SanoffRichard M GoldbergAnastasia IvanovaSeamus O'ReillySamer S KasbariRichard D KimRay McDermottDominic T MooreWilliam ZamboniWilliam GroganAllen Lee CohnTanios S Bekaii-SaabGregory LeonardTheresa RyanOlugbenga O OlowokureNishan H FernandoJohn McCaffreyBassel F El-RayesAnne M HorganGary Bradley SherrillGeorge Hosni YacoubBert H O'NeilPublished in: Cancer (2018)
The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018. © 2018 American Cancer Society.